NIM
RPRX icon

NEOS Investment Management’s Royalty Pharma RPRX Stock Holding History

NEOS Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,589
Closed -$241K – 572
2023
Q4 		$241K Buy
8,589
+409
+5% +$11.2K 0.02% 456
2023
Q3 		$222K Buy
+8,180
New +$243K 0.03% 334

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

NEOS Investment Management's RPRX Position: Q1 2024 in Review

NEOS Investment Management sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 8,589 shares — an estimated $241K sold.

NEOS Investment Management first reported a position in RPRX in Q3 2023 and held it in 2 quarters. The position peaked at $241K in Q4 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • NEOS Investment Management reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
  • NEOS Investment Management sold 8,589 Royalty Pharma shares in Q1 2024, an estimated $241K.
  • NEOS Investment Management first reported a position in Royalty Pharma in Q3 2023 and held it in 2 quarters.
  • NEOS Investment Management's Royalty Pharma position peaked at $241K in Q4 2023.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on NEOS Investment Management's 13F filing for Q1 2024, filed 13 May 2024.